Table 1.

Demographics. Age, sex, BMI, and PASI score prior to (PASI 0) and following (PASI 1) treatment with adalimumab of each participant in the study.

Study ID	AGE	SEX	BMI	PASI 0	PASI 1
HUM-001	48	Male	27.9	15.8	8.4
HUM-002	46	Male	22.3	15.8	5.0
HUM-003	39	Male	31.6	17.2	9.4
HUM-004	53	Male	NA	8.0	2.8
HUM-005	38	Male	28.1	12.1	9.5
HUM-006	40	Male	27.3	17.9	8.6
HUM-007	30	Male	41.6	17.2	16.4
HUM-008	25	Male	20.5	22.5	11.3
HUM-009	34	Male	NA	13.3	2.0
HUM-010	34	Male	25.1	18.3	17.1
HUM-011	34	Male	38.9	16.3	11.9
HUM-012	25	Female	31.4	13.8	7.1
HUM-013	30	Female	NA	22.6	13.2
HUM-014	34	Female	25.4	8.5	2.9
HUM-015	57	Female	27.5	13.7	8.4
HUM-016	22	Male	29.8	14.6	8.3
HUM-017	31	Female	34.6	19.3	13.3
HUM-018	25	Male	29.8	13.2	1.3
HUM-019	47	Male	31.7	15.6	8.9
HUM-020	30	Female	32.5	16.4	9.2
HUM-021	28	Female	24.0	13.6	8.3
HUM-022	56	Male	NA	12.9	7.0
HUM-023	32	Male	41.0	12.5	9.7
HUM-024	35	Male	25.1	9.7	5.0
HUM-025	43	Male	43.0	20.1	10.9
HUM-026	39	Male	28.7	13.3	5.2
HUM-027	41	Female	25.1	12.0	3.6
HUM-029	46	Male	39.5	13.2	8.9
HUM-030	24	Male	28.4	15.2	6.9
HUM-031	24	Female	33.8	30.4	20.1